Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

20.54USD
16 Jan 2018
Change (% chg)

-- (--)
Prev Close
$20.54
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
214,149
52-wk High
$49.21
52-wk Low
$19.73

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME.FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME.FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019.FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION.  Full Article

Five Prime Therapeutics Submits Investigational New Drug Application For FPA150
Thursday, 4 Jan 2018 

Jan 3 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150.FIVE PRIME THERAPEUTICS INC - ANTICIPATES INITIATING A PHASE 1 TRIAL OF FPA150 DURING FIRST HALF OF 2018.  Full Article

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​.  Full Article

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Five Prime posts Q3 loss of $1.54 per share
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Five Prime Therapeutics Inc :Five prime announces third quarter 2017 results and provides business update.Q3 loss per share $1.54.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.Five prime therapeutics inc - ‍collaboration revenue for q3 of 2017 increased by $1.6 million to $8.3 million​.  Full Article

Five Prime Therapeutics appoints Aron Knickerbocker as CEO
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Five Prime Therapeutics Inc :Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018.Five Prime Therapeutics Inc - ‍ selected Aron Knickerbocker to succeed Lewis Williams, as president and CEO​.Five Prime Therapeutics Inc - ‍ Knickerbocker will maintain chief operating officer position until end of 2017​.  Full Article

Five Prime announces Q2 2016 results and provides business update
Friday, 5 Aug 2016 

Five Prime Therapeutics Inc : Five prime announces second quarter 2016 results and provides business update . Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S . Q2 revenue $9.2 million versus $6.3 million . Q2 loss per share $0.49 .Q2 revenue view $6.4 million -- Thomson Reuters I/B/E/S.  Full Article

Five Prime says entered amendment to license agreement with Galaxy Biotech
Friday, 20 May 2016 

Five Prime Therapeutics Inc : Entered into an amendment to exclusive license agreement with galaxy biotech, llc - sec filing . Co, galaxy revised milestone definitions, reduced certain milestone payments,added 4 development-related milestone payments .Amount of development-related milestone payments that fiveprime will be obligated to pay was decreased by $0.5 million.  Full Article

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME